Grant: Collaborative Health Research Projects
University of Toronto
$281,500.00
Rapid Microfluidic-Based Point-of-Care Assessment of Epigenetic Marks for Diagnosis, Prognosis and Response to Therapy in Critical Illness
FY 2020-21
Summary
Sepsis, whole body inflammation and organ failure triggered by an overwhelming and
unbalanced response to infection, incurs enormous human and health care costs. Globally,
over 30 million people are affected each year, at least a quarter of whom will die. The
sequelae include physical, mental, and psychological disability. Currently, no specific
treatments exist. For cancer patients, personalizing treatment on the basis of molecular
characteristics of a tumor is simply good practice. There is an urgent need to do the same for
sepsis. We have identified tags on DNA (DNA methylation marks) that can classify septic vs.
non-septic patients, the likelihood of poor outcomes (death and organ failure) and response to
therapy (blood pressure medications). In parallel, our partners have developed and patented
a point-of-care device that uses an innovative microfluidic approach to isolate DNA from
whole blood. We propose to adapt this technology to develop a prototype able to perform
automated measurements of DNA marks from patients using whole blood; to test our device
on banked DNA and whole blood samples; to use predictive modeling to integrate clinical and
molecular data to validate outcome prediction and response to therapy in an independent
cohort; and to test the performance of our prototype and precision marks prospectively in a
real-world situation. Both the technology and biomarker detection approaches have never
been tried for sepsis before. This proposal brings together bioengineers, health research
scientists, bioinformaticians, physicians and clinical biochemists. Successful completion will
provide a Lab-on-chip technology employing low-cost industrially manufacturable polymer
microfluidic devices powered by an advanced patented centrifugal microfluidic technology that
promises to be a disruptive innovation in the way to integrate and deploy genomic knowledge
practical devices that will impact clinical practices and the care of the critically ill.
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
549575-2020
Name nom
Dos Santos, Claudia Chimisso
Department département
Physiology
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
281500
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Installment
inst:1 - 3
Partie
3
Nb partie
3
Application title
Rapid Microfluidic-Based Point-of-Care Assessment of Epigenetic Marks for Diagnosis, Prognosis and Response to Therapy in Critical Illness
Keyword
NSERC
Application summary
Sepsis, whole body inflammation and organ failure triggered by an overwhelming and
unbalanced response to infection, incurs enormous human and health care costs. Globally,
over 30 million people are affected each year, at least a quarter of whom will die. The
sequelae include physical, mental, and psychological disability. Currently, no specific
treatments exist. For cancer patients, personalizing treatment on the basis of molecular
characteristics of a tumor is simply good practice. There is an urgent need to do the same for
sepsis. We have identified tags on DNA (DNA methylation marks) that can classify septic vs.
non-septic patients, the likelihood of poor outcomes (death and organ failure) and response to
therapy (blood pressure medications). In parallel, our partners have developed and patented
a point-of-care device that uses an innovative microfluidic approach to isolate DNA from
whole blood. We propose to adapt this technology to develop a prototype able to perform
automated measurements of DNA marks from patients using whole blood; to test our device
on banked DNA and whole blood samples; to use predictive modeling to integrate clinical and
molecular data to validate outcome prediction and response to therapy in an independent
cohort; and to test the performance of our prototype and precision marks prospectively in a
real-world situation. Both the technology and biomarker detection approaches have never
been tried for sepsis before. This proposal brings together bioengineers, health research
scientists, bioinformaticians, physicians and clinical biochemists. Successful completion will
provide a Lab-on-chip technology employing low-cost industrially manufacturable polymer
microfluidic devices powered by an advanced patented centrifugal microfluidic technology that
promises to be a disruptive innovation in the way to integrate and deploy genomic knowledge
practical devices that will impact clinical practices and the care of the critically ill.